Market cap
₹17,981 Cr
Recently Viewed
Clear AllNSE: COHANCE | BSE: 543064
₹470.40
₹-22.90
(-4.64%)
As on 29-Apr-2026 13:09IST
Market cap
₹17,981 Cr
Revenue (TTM)
₹2,051 Cr
P/E Ratio
89.2
P/B Ratio
4.7
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹202 Cr
ROE
14.2 %
ROCE
18.4 %
Industry P/E
46.42
EV/EBITDA
40.4
Debt to Equity
0
Book Value
₹99.8
EPS
₹6.1
Face value
1
Shares outstanding
382,567,140
CFO
₹2,299.99 Cr
EBITDA
₹2,936.21 Cr
Net Profit
₹2,218.76 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cohance Lifesciences
| -11.0 | 55.4 | 23.3 | -59.0 | -0.1 | -2.8 | -- |
|
BSE Healthcare
| 3.0 | 5.4 | 8.4 | 5.1 | 24.8 | 13.9 | 11.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Cohance Lifesciences
| -52.9 | 58.1 | 46.0 | 0.3 | 6.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cohance Lifesciences
|
470.4 | 17,980.7 | 2,051.5 | 180.5 | 11.6 | 7.7 | 89.2 | 4.7 |
| 2,499.0 | 20,337.2 | 1,215.1 | 284.8 | 28.7 | 21.1 | 70.9 | 13.4 | |
| 720.7 | 17,390.4 | 5,092.5 | 545.5 | 15.9 | 14.1 | 31.9 | 3.9 | |
| 927.2 | 14,754.2 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.1 | 2.2 | |
| 1,094.6 | 19,630.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,787.6 | 20,712.5 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1030.4 | 3.6 | |
| 162.6 | 21,587.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.6 | |
| 966.5 | 15,977.6 | 1,284.3 | 134.4 | -- | 30.7 | 118.9 | 13.1 | |
| 437.1 | 17,640.7 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.1 | 3.7 | |
| 1,403.8 | 22,893.5 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1040.6 | 4.9 |
Two pharmaceutical giants announce merger
2 min read•By Satyajit Sen
Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United... States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluorescent dyes; pellets and finished dosage forms; and specialty chemicals, including agrochemicals. It serves pharmaceutical, biotechnology, and chemical companies. The company was formerly known as Suven Pharmaceuticals Limited and changed its name to Cohance Lifesciences Limited in May 2025. The company was founded in 1989 and is headquartered in Hyderabad, India. Cohance Lifesciences Limited is a subsidiary of Berhyanda Limited. Read more
Incorporated
2018
Chairman
Vivek Sharma
Managing Director
--
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Cohance Lifesciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View AnnouncementsClarification With Respect To Volume Movement
13-Apr-2026No News & Announcements are available.
The share price of Cohance Lifesciences Ltd is ₹470.40 (NSE) and ₹469.90 (BSE) as of 29-Apr-2026 13:09 IST. Cohance Lifesciences Ltd has given a return of -0.11% in the last 3 years.
The P/E ratio of Cohance Lifesciences Ltd is 89.15 times as on 29-Apr-2026, a 92 premium to its peers’ median range of 46.42 times.
The P/B ratio of Cohance Lifesciences Ltd is 4.71 times as on 29-Apr-2026, a 26 premium to its peers’ median range of 3.73 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
110.23
|
17.58
|
|
2024
|
57.37
|
8.41
|
|
2023
|
29.26
|
6.93
|
|
2022
|
34.66
|
10.30
|
|
2021
|
34.80
|
10.68
|
The 52-week high and low of Cohance Lifesciences Ltd are Rs 1,165.90 and Rs 266.70 as of 29-Apr-2026.
Cohance Lifesciences Ltd has a market capitalisation of ₹ 17,981 Cr as on 29-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Cohance Lifesciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.